This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SCLN SciClone Pharmaceuticals (SCLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About SciClone Pharmaceuticals Stock (NASDAQ:SCLN) 30 days 90 days 365 days Advanced Chart Get SCLN alerts:Sign Up Key Stats Today's Range$11.15▼$11.1550-Day Range N/A52-Week Range$8.55▼$11.43VolumeN/AAverage Volume444,833 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.Read More… Receive SCLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciClone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLN Stock News HeadlinesCumberland announces NMPA approval of Vibativ injection in ChinaFebruary 18, 2025 | markets.businessinsider.comPWRHF PWR Holdings LimitedOctober 19, 2024 | seekingalpha.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 7, 2025 | Brownstone Research (Ad)SciClone Pharmaceuticals (Holdings) LtdDecember 27, 2023 | morningstar.comSciClone Reaches New 52-Week High (SCLN)April 5, 2023 | thestreet.comDawn Health partners with leading pharmaceutical company to transform chronic careFebruary 27, 2023 | finance.yahoo.comSciClone Pharmaceuticals (Holdings) Limited (6600.HK)February 9, 2023 | finance.yahoo.comSee More Headlines SCLN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of SciClone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that SciClone Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), (ONCYF) (ONCYF), Gilead Sciences (GILD), Rite Aid (RAD), Skyworks Solutions (SWKS), Imunon (CLSN) and CTI BioPharma (CTIC). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SCLN CIK880771 Webwww.sciclone.com Phone+1-650-3583456FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SCLN) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciClone Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share SciClone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.